Abstract: A DC brushless motor is provided, which includes a housing, a motor assembly, a control board and a dividing plate. Wherein, the motor assembly is arranged in the housing, and a connecting terminal is arranged on it. The control board is arranged in the housing and electrically connected with the connecting terminal. The dividing plate is arranged in the housing and is used to divide the motor assembly from the control board. The disclosure is used to solve a problem of complicated internal wiring of a motor caused by a division of the motor and a controller of the conventional DC brushless motor.

Abstract: The present disclosure provides a random particle generation method based on particle size distribution, which can accord with the particle size distribution characteristics of a geological structure. According to this method, random particle generation is adopted, so that a common spherical structure is avoided, and a generated particle structure is very similar to a real soil structure. Based on actual particle size distribution, particles with different particle sizes are generated by batch generation, particle seeds are generated at random pore locations, and particles are generated based on the seeds. By providing a random particle generation method based on particle size distribution, a soil structure in a form of porous media can be restored by means of simulation, which thus provides a porous medium model for the research of groundwater infiltration and fossil energy exploitation.

Abstract: A method for treating a sludge derived from sewage or wastewater, the method comprising subjecting the sludge to a treatment step at a pH of 8.9 or greater and a free ammonia (FA) content of 100 mg NH3—N/L or greater. The treated sludge may be fed to a bioreactor to produce methane.

Abstract: A method for treating a sludge derived from sewage or wastewater, the method comprising subjecting the sludge to a treatment step at a pH of 8.9 or greater and a free ammonia (FA) content of 100 mg NH3—N/L or greater. The treated sludge may be fed to a bioreactor to produce methane.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: An exenatide-containing composition is in the form of microspheres, which are prepared by using exenatide acetate and polylactic-co-glycolic acid (PLGA) as raw materials, and the content of acetic acid in the prepared composition is lower than 0.01%. A method for preparing the exenatide-containing microspheres includes selecting a cleaning fluid of a proper external water phase and a proper amount to clean microspheres, and selecting a proper re-drying temperature to cure the microspheres after the microspheres are freeze-dried.

Abstract: The present document discloses a method for reducing a number of access times of a multimode terminal. The method includes the following steps: judging a network state of the terminal; acquiring signal intensity of a base station, calculating network delay time according to the signal intensity of the base station, and setting a timer according to the network delay time; and switching a data service when the timer has timed out. The present document further discloses an apparatus for reducing a number of access times of a multimode terminal.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: An exenatide-containing composition is in the form of microspheres, which are prepared by using exenatide acetate and polylactic-co-glycolic acid (PLGA) as raw materials, and the content of acetic acid in the prepared composition is lower than 0.01%. A method for preparing the exenatide-containing microspheres includes selecting a cleaning fluid of a proper external water Phase and a proper amount to clean microspheres, and selecting a proper re-drying temperature to cure the after the microspheres are freeze dried.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: The present document discloses a method for reducing a number of access times of a multimode terminal. The method includes the following steps: judging a network state of the terminal; acquiring signal intensity of a base station, calculating network delay time according to the signal intensity of the base station, and setting a timer according to the network delay time; and switching a data service when the timer has timed out. The present document further discloses an apparatus for reducing a number of access times of a multimode terminal.

Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

Abstract: A method for displaying an interface is provided. The method includes displaying an icon of at least one first object in a first area of a display interface, displaying an icon of a second object in a second area of the display interface if the second object exists, the second object and the first object belong to a same level and different categories, wherein if one of the at least one first object is selected, the method further includes: hiding an icon of a first object which is not selected in the first area, displaying an icon of each sub-object of the selected first object in the second area, displaying an icon of a first object in the first area which is not selected in a third area of the display interface and displaying the icon of the second object in a fourth area of the display interface.

Abstract: A method for displaying an interface is provided. The method includes displaying an icon of at least one first object in a first area of a display interface, displaying an icon of a second object in a second area of the display interface if the second object exists, the second object and the first object belong to a same level and different categories, wherein if one of the at least one first object is selected, the method further includes: hiding an icon of a first object which is not selected in the first area, displaying an icon of each sub-object of the selected first object in the second area, displaying an icon of a first object in the first area which is not selected in a third area of the display interface and displaying the icon of the second object in a fourth area of the display interface.

Abstract: Sustained release triptorelin microspheres include triptorelin or a salt of triptorelin, a copolymer of lactide and glycolide, and glucose or mannitol. The sustained release triptorelin microspheres have a relatively high initial release after administration, which allows the drug to produce its pharmaceutical effects immediately and to maintain long-term steady pharmaceutical effects.

Abstract: A method for industrially preparing a nitrogen substituted 6-amino-5,6,7,8-tetrahydronaphthol includes reacting a nitrogen substituted amino-5,6,7,8-tetrahydronaphthol compound of formula (II) with a 2-substituted ethyl sulfonate compound of formula (III) under an alkaline condition and in the presence of a sulfite.